Tim Meyer

32.3k total citations · 13 hit papers
237 papers, 13.8k citations indexed

About

Tim Meyer is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Tim Meyer has authored 237 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 104 papers in Hepatology and 91 papers in Epidemiology. Recurrent topics in Tim Meyer's work include Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Neuroendocrine Tumor Research Advances (55 papers) and Lung Cancer Research Studies (47 papers). Tim Meyer is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Neuroendocrine Tumor Research Advances (55 papers) and Lung Cancer Research Studies (47 papers). Tim Meyer collaborates with scholars based in United Kingdom, United States and Germany. Tim Meyer's co-authors include Andrew K. Burroughs, Gonzalo Sapisochín, Anna Saborowski, Riad Salem, Arndt Vogel, Josep M. Llovet, Gordon Rustin, Tu Vinh Luong, Bruno Sangro and Martyn Caplin and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Tim Meyer

231 papers receiving 13.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocellular carcinoma

2022 1.3k citations Tim Meyer et al. profile →
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

2020 850 citations Masatoshi Kudo, Tim Meyer et al. Journal of Clinical Oncology profile →
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2018 712 citations Arndt Vogel, Tim Meyer et al. Annals of Oncology profile →
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

2021 633 citations Tim Meyer et al. profile →
Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies

2006 617 citations Tim Meyer, Andrew K. Burroughs et al. profile →
A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability

2012 498 citations Tu Vinh Luong, Tim Meyer et al. profile →
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

2017 331 citations Tim Meyer, Philip J. Johnson et al. profile →
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

2021 306 citations Arndt Vogel, Tim Meyer et al. Annals of Oncology profile →
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

2019 299 citations Tim Meyer, Suzanne L. Topalian et al. Journal of Clinical Oncology profile →
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020 240 citations Tim Meyer, Peter R. Galle et al. profile →
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

2024 145 citations Bruno Sangro, Maxime Ronot et al. Journal of Hepatology profile →
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

2023 136 citations Masatoshi Kudo, Tim Meyer et al. profile →
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Tim Meyer

Since Specialization

Citations

This map shows the geographic impact of Tim Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Meyer more than expected).

Fields of papers citing papers by Tim Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Meyer. The network helps show where Tim Meyer may publish in the future.

Co-authorship network of co-authors of Tim Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Meyer. A scholar is included among the top collaborators of Tim Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Meyer. Tim Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detection of autoantibodies against Interferon Type I in patients with autochthonous West Nile Virus encephalitis 2025 ·Brain Behavior & Immunity - Health ·(unknown), (unknown), Christian Meisel, Tim Meyer, (unknown), Victor M. Corman, Christiana Franke, Thomas J. Schneider	0
2	Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study 2025 ·Journal of Clinical Oncology ·Shailender Bhatia, Suzanne L. Topalian, William H. Sharfman, Tim Meyer, Neil Steven, Christopher D. Lao, Lorena Fariñas-Madrid, Lot A. Devriese, Kathleen N. Moore, Robert L. Ferris, Yoshitaka Honma, Ileana Elias, Anjaiah Srirangam, Charlie Garnett‐Benson, Michelle Lee, Paul Nghiem	7
3	EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma breakdown → 2024 ·Journal of Hepatology ·Bruno Sangro, (unknown), Maxime Ronot, Valérie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter R. Galle, Laura A. Dawson, María Reig	145
4	Rare primary liver cancers: An EASL position paper 2024 ·Journal of Hepatology ·Henning Wege, Claudia Campani, Ruben H. de Kleine, Tim Meyer, Jean‐Charles Nault, Timothy M. Pawlik, María Reig, Jens Ricke, Christine Sempoux, Guido Torzilli, Jessica Zucman‐Rossi	4
5	Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review 2023 ·Liver Cancer ·Arndt Vogel, Robin Kate Kelley, Philip J. Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa	6
6	Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease 2022 ·European Respiratory Journal ·(unknown), Tim Meyer, Mariana Schürmann, (unknown), Harald Bias, David J. Krieger, Torsten Bauer, Petra Bächer, Johannes Helmuth, Hans‐Dieter Volk, Dirk Schürmann, Alexander Scheffold, Christian Meisel	5
7	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors 2022 ·Clinical Cancer Research ·(unknown), Yien Ning Sophia Wong, (unknown), Ayse U. Akarca, Pawan Dhami, (unknown), Lucía Conde, Javier Herrero, Olagunju Ogunbiyi, Amir Gander, Tu Vinh Luong, (unknown), Martyn Caplin, Christos Toumpanakis, Karl S. Peggs, Sergio A. Quezada, Teresa Marafioti, Tim Meyer	7
8	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma 2021 ·Liver Cancer ·Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek‐Yeol Ryoo, Philippe Merle, Joong‐Won Park, Jean‐Frédéric Blanc, Ho Yeong Lim, Albert Tran, Yi‐Wah Chan, Paul R. McAdam, Evelyn N. Wang, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	22
9	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong‐Won Park, Thomas Yau, Stephen L. Chan, Jean‐Frédéric Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	66
10	SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo 2020 ·Annals of Oncology ·Anthony B. El-Khoueiry, Tim Meyer, Ann‐Lii Cheng, Lorenza Rimassa, Seema Sen, Steven Milwee, Robin Kate Kelley, G.K. Abou-Alfa	12
11	219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study 2016 ·Annals of Oncology ·Ignacio Melero, Bruno Sangro, Tung On Yau, (unknown), (unknown), Todd S. Crocenzi, T.-Y. Kim, Su Pin Choo, Jörg Trojan, Tim Meyer, (unknown), Winnie Yeo, (unknown), (unknown), (unknown), L. Láng, Jaclyn Neely, (unknown)	4
12	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms 2015 ·Clinical Cancer Research ·Mohid S. Khan, Amy A. Kirkwood, Theodora Tsigani, Helen L. Lowe, Robert M. Goldstein, John A. Hartley, Martyn Caplin, Tim Meyer	66
13	Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer 2013 ·Expert Review of Anticancer Therapy ·Robert M. Goldstein, Jane Sosabowski, (unknown), Kerry Chester, Tim Meyer	20
14	γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000) 2012 ·Clinical Cancer Research ·Jenny Wu, Peter H. Clingen, Victoria J. Spanswick, (unknown), Tim Meyer, Igor Puzanov, Duncan I. Jodrell, Daniel Hochhauser, John A. Hartley	50
15	Oral tolerance induction in humans 2012 ·Experimental and Molecular Pathology ·Tim Meyer, Reiner Ullrich, Martin Zeitz	9
16	Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors 2011 ·Clinical Cancer Research ·Mohid S. Khan, Theodora Tsigani, Mohammed Rashid, (unknown), Dominic Yu, Tu Vinh Luong, Martyn Caplin, Tim Meyer	90
17	Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs) 2011 ·UCL Discovery (University College London) ·Khan, Theodora Tsigani, Jorge García-Hernández, Martyn Caplin, Tim Meyer	1
18	Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization 2007 ·The Journal of Immunology ·Lakshmana Ayaru, Stephen P. Pereira, Akeel Alisa, Ansar A. Pathan, Roger Williams, (unknown), Andrew K. Burroughs, Tim Meyer, Shahriar Behboudi	121
19	Importance of human papillomaviruses for the development of skin cancer. 2001 ·PubMed ·Tim Meyer, R. Arndt, Enno Christophers, Ingo Nindl, Eggert Stockfleth	66
20	In vivo therapy of malignant melanoma by means of antagonists of αv integrins 2000 ·International Journal of Cancer ·Francesc Mitjans, Tim Meyer, Claus Fittschen, Simon L. Goodman, Alfred Jonczyk, John F. Marshall, Germán Reyes, Jaume Piulats	127

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact